Cargando…

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms

Detalles Bibliográficos
Autores principales:	Avogaro, Angelo, Albiero, Mattia, Menegazzo, Lisa, de Kreutzenberg, Saula, Fadini, Gian Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Hypertension
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632194/ https://www.ncbi.nlm.nih.gov/pubmed/21525470 http://dx.doi.org/10.2337/dc11-s239

Ejemplares similares

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1α
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery Disease
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
por: Fadini, Gian Paolo, et al.
Publicado: (2013)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Effects of androgens on endothelial progenitor cells in vitro and in vivo
por: Fadini, Gian Paolo, et al.
Publicado: (2009)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
por: Avogaro, Angelo, et al.
Publicado: (2014)

Reparatory
Publicado: (1867)

Time Course and Mechanisms of Circulating Progenitor Cell Reduction in the Natural History of Type 2 Diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Endothelial Factors and Diabetic Nephropathy
por: Karalliedde, Janaka, et al.
Publicado: (2011)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms
por: de Kreutzenberg, Saula Vigili, et al.
Publicado: (2010)

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2021)

A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease
por: Vigili de Kreutzenberg, Saula, et al.
Publicado: (2022)

Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes
por: Parati, Gianfranco, et al.
Publicado: (2013)

Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Impaired Hematopoietic Stem/Progenitor Cell Traffic and Multi-organ Damage in Diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Intolerance to Statins: Mechanisms and Management
por: Bitzur, Rafael, et al.
Publicado: (2013)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

RAS Blockade for Every Diabetic Patient: Pro and Con
por: Ruilope, Luis M., et al.
Publicado: (2011)

Antihypertensive Treatment and Blood Pressure in Diabetic and Nondiabetic Patients: The lower, the better?
por: Mancia, Giuseppe, et al.
Publicado: (2011)

Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment
por: Ritz, Eberhard
Publicado: (2011)

Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity
por: Tedesco, Serena, et al.
Publicado: (2019)

The Role of Nocturnal Blood Pressure and Sleep Quality in Hypertension Management
por: Cappuccio, Francesco P
Publicado: (2020)

Benefits of Tight Blood Pressure Control in Diabetic Patients With Hypertension: Importance of early and sustained implementation of effective treatment strategies
por: Parati, Gianfranco, et al.
Publicado: (2011)

Diuretic Treatment of Hypertension
por: Grossman, Ehud, et al.
Publicado: (2011)

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Blood Pressure: The Lower, the Better: The con side
por: Grossman, Ehud
Publicado: (2011)

The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg
por: Schrader, J, et al.
Publicado: (2009)

Individualization of Antihypertensive Drug Treatment
por: Mancia, Giuseppe, et al.
Publicado: (2013)

Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Hypertension
por: Grossman, Ehud
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fo1314nd45ao5nst07a9vrkfkj